Document:

Exhibit
10.1

CONVERTIBLE
PROMISSORY NOTE

 

THIS
NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE
SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT COVERING THIS NOTE OR SUCH SHARES UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR THE DELIVERY OF AN OPINION
OF COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. THIS NOTE IS ALSO SUBJECT TO RESTRICTIONS ON TRANSFER. 

 

Regen
BioPharma, Inc.

 

	Issue
    Date:	4/6/2016	Minimum
    Investment:	 Principal
    Amount: $50,000

Total
Offering : $10 million (equals 10% royalty on NR2F6 transaction as discussed in this document

 

1.
Terms. For value received, the Regen BioPharma, Inc., a Nevada corporation (the “Company”) hereby absolutely
and unconditionally promises to pay to the order of ________ ON DEMAND THREE YEARS AFTER THE Issue Date, the principal amount
of One Hundred Thousand Dollars ($100,000) and interest on the whole amount of said principal sum outstanding and remaining from
time to time unpaid (the “Note”), commencing from the date hereof and continuing until payment in full of this Note
or conversion as hereinafter provided, at an annual rate equal to eight percent (8%) simple interest. Interest shall be payable
quarterly upon demand or upon conversion pursuant to Section 2 hereunder. Interest shall be computed on the basis of the actual
number of days elapsed divided by 365. Principal and interest shall be payable in lawful money of the United States of America,
at the principal place of business of the Lender or at such other place as the Lender may have designated from time to time in
writing to the Company.

 

2.
Conversion.

 

2.1
Conversion Right. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid
principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue
Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed
or reclassified at the conversion price (the “Conversion Price”) determined as provided herein (a “Conversion”).
The Lender shall have the right to convert one hundred percent (100%) of the Principal Amount immediately upon execution of this
agreement and any accrued interest may be converted as well.

 

The
number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the principal
amount of this Note to be converted (the “Conversion Amount”) by the applicable Conversion Price as defined in this
Section 2 then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the “Notice
of Conversion”), delivered to the Company by the Lender on such conversion date (the “Conversion Date”).

 

    	1 

    	 

    

2.2
Conversion Price. The “Conversion Price” shall be defined as :

 

	 	(a)	For
    the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount
    to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period
    ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

 

	 	(b)	For
    the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year
    2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day
    (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever
    is greater).

 

	 	(c)	For
    the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”)
    a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined
    below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is
    greater).

 

	 	(d)	“Trading
    Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”)
    as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or,
    if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal
    securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security
    is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security
    that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated
    for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually
    determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable
    for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock
    is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported
    by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings,
    combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating
    to the Lender’s securities.

 

2.3
Method of Conversion. Subject to Section 2.1, this Note may be converted by the Lender by submitting to the Company a Notice
of Conversion by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 5:00
p.m., New York, New York time. The Lender shall not be required to physically surrender this Note to the Company unless the entire
unpaid principal amount of this Note is so converted. The Lender and the Company shall maintain records showing the principal
amount so converted and the dates of such conversions so as not to require physical surrender of this Note upon each such conversion.
In the event of any dispute or discrepancy, such records of the Company shall, prima facie, be controlling and determinative in
the absence of manifest error. Notwithstanding the foregoing, if any portion of this Note is converted as aforesaid, the Lender
may not transfer this Note unless the Lender first physically surrenders this Note to the Company, whereupon the Company will
forthwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the Lender (upon payment by the
Lender of any applicable transfer taxes) may request, representing in the aggregate the remaining unpaid principal amount of this
Note.

 

    	2 

    	 

    

Upon
receipt by the Company from the Lender of a facsimile transmission, e-mail, or other reasonable means of communication of a Notice
of Conversion meeting the requirements for conversion, the Company shall issue and deliver or cause to be issued and delivered
to or upon the order of the Lender certificates for the Common Stock issuable upon such conversion within five (5) business days
after such receipt. Upon receipt by the Company of a Notice of Conversion, the Lender shall be deemed to be the Lender of record
of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest
on this Note shall be reduced to reflect such conversion. All rights with respect to the portion of this Note being so converted
shall forthwith terminate except the right to receive the Common Stock or other securities as herein provided on such conversion.
In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Company is participating
in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”) program, upon request
of the Lender, the Company shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock
issuable upon conversion to the Lender by crediting the account of Lender’s Prime Broker with DTC through its Deposit Withdrawal
Agent Commission (“DWAC”) system.

 

2.4
Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not
be sold or transferred unless (i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the
Company or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall be in form, substance
and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred
may be sold or transferred pursuant to an exemption from such registration or (iii) such shares are sold or transferred pursuant
to Rule 144 under the Act (or a successor rule) ("Rule 144") or (iv) such shares are transferred to an "affiliate"
(as defined in Rule 144) of the Company who agrees to sell or otherwise transfer the shares only in accordance with this Section
2.5 and who is an Accredited Investor as the term Accredited Investor is defined in Rule 501 of Regulation D, promulgated under
the Act.

 

Subject
to the removal provisions set forth below, until such time as the shares of Common Stock issuable upon conversion of this Note
have been registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for shares of issuable upon conversion of this Note
that has not been so included in an effective registration statement or that has not been sold pursuant to an effective registration
statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

 

    	3 

    	 

    

"NEITHER
THE ISSUANCE OR  SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)
IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
(B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS
NOT REQUIRED UNDER SAID ACT."

 

The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope customary
for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock may be made
without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company or its transfer
agent with reasonable assurances that the Common Stock issuable upon conversion of this Note (to the extent such securities are
deemed to have been acquired on the same date) can be sold pursuant to Rule 144 or (iii) in the case of the Common Stock issuable
upon conversion of this Note, such security is registered for sale by under an effective registration statement filed under the
Act or (iv) otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular
date that can then be immediately sold.

 

3.
Prepayment. Notwithstanding anything to the contrary contained herein, the Company shall have the right, exercisable on
not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including
outstanding principal and accrued interest. Any notice of prepayment hereunder shall be delivered to the Lender at its registered
addresses and shall state that the Company is exercising its right to prepay the Note and the date of prepayment, which shall
be not more than three (3) Trading Days from the date of the prepayment notice. Upon receipt of a prepayment notice, Lender shall
have the right, but not the obligation, to accelerate the conversion period specified in Section 2.1 and convert that portion
of the outstanding principal balance which is subject to prepayment to Common Shares as provided for in Section 2.

 

4.
Right to Receive Royalty

 

4.1
Definitions

 

“Transaction
Event” shall mean either of:

 

	 	(a)	The
    sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

 

	 	(b)	The
    granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop
    and/or commercialize the Company’s proprietary NR2F6 intellectual property

 

Upon
closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received
by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

 

    	4 

    	 

    

5.
Events of Default.

 

5.1
The following shall constitute events of default (individually an "Event of Default"):

 

(a)
default in the payment, when due or payable, of an obligation to pay interest or principal under this Note, which default is not
cured by payment in full of the amount due within thirty (30) days from the date that the Lender receives notice of the occurrence
of such default;

 

(b)
filing of a petition in bankruptcy or the commencement of any proceedings under any bankruptcy laws by or against the Company,
which filing or proceeding, is not dismissed within ninety (90) days after the filing or commencement thereof; or

 

(c)
failure of the Company to comply in any way with the terms, covenants or conditions contained in this Note.

 

5.2
If an Event of Default shall occur and be continuing, the Lender may, at its option, declare this Note to be immediately due and
payable without further notice or demand, whereupon this Note shall become immediately due and payable without presentment, demand
or protest, all of which are hereby waived by the Company.

 

6.
Transfer of Note. This Note may not be transferred or assigned other than a transfer or assignment to an Affiliate of the
Lender. As used herein, the term “Affiliate” means an entity that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the Lender.

 

7.
Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and
any other formalities of any kind.

 

8.
Amendment, Modification or Termination. This Note may only be modified, amended, or terminated (other than by payment in
full) by an agreement in writing signed by the Company and the Lender. No waiver of any term, covenant or provision of this Note
shall be effective unless given in writing by the Lender.

 

9.
Governing Law. This Note and the obligations of the Company hereunder shall be governed by and interpreted and determined
in accordance with the laws of the State of California (excluding the laws and rules of law applicable to conflicts or choice
of law).

    	5 

    	 

    

 

IN
WITNESS WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

 

 

	 	REGEN
    BIOPHARMA, INC.	 	 
	 	 	 	 
	 	/s/
    David Koos	 	Dated:4/6/2016
	 	David
        Koos

        Chairman
        and CEO
	 	 
	 	 	 	 

 

The
foregoing Convertible Promissory Note is hereby accepted and agreed to by the undersigned on and as of the date first above written.

 

 

    	6 

    	 

    

 

EXHIBIT
A

 

NOTICE
OF CONVERSION

 

The
undersigned hereby elects to convert $ _________ principal amount and $____________ accrued interest of the Note into that number
of shares of Common Stock to be issued pursuant to the conversion of the Note as set forth below of REGEN BIOPHARMA, INC. according
to the conditions of the convertible note of the Company dated as of MONTH DAY, 201X as of the date written below.

 

	Dater
    of Conversion:	 
	Applicable Conversion
    Price:	 
	(Attached
    Bloomberg price documentation)	 
	Number of SHares of
    Common Stock to be Issued Pursuant to Conversion of the Note:	 
	Amount of Principal
    Balance Due Remaining Under the Note After This Conversion:	 

 

 

Checked
box corresponds to applicable instructions:

 

☐
The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the
undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system (“DWAC Transfer”).

 

	Name of
    DTC Prime Broker:	 
	Account Number:	 

 

☐
The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock
set forth below in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

 

	Name:	 
	Address:	 
	 	 
	 	 
	Phone:	 

 

 

 

	XXXXXXXXXXXXXXX,
    LLC	 	 
	XXXXXXX	 	Date

 

 

    	7Exhibit
10.2

THIS
UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation
(the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”),
a _______ whose address is _____________. 

WHEREAS:

The
Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions
set forth herein.

The
Company desires to issue and sell Units to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE,
IT IS AGREED AS FOLLOWS

	 	1.	Units

 

Each
Unit shall consist of one ( 1) shares of the common stock of the Company and three (3) shares of the Series A Preferred Stock
of the Company

	 	2.	Purchase
    Price

 

The
purchase price per Unit ( “Purchase Price”), payable in US Dollars, shall be 5 cents per unit.(Each Unit consists
of one share of common and three shares of the Series A Preferred Stock of the Company)

	 	3.	Form
    of Payment

 

The
Purchaser shall pay the Purchase Price per Unit multiplied by that number of Units Purchased by wire transfer of immediately available
funds to the Company

	WIRE
    INSTRUCTIONS:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

    	1 

    	 

    

	 	4.	Issuance
    of Units

 

5
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Units
purchased 

	 	5.	Purchaser’s
    Representations and Warranties

 

	 	(a)	As
    of the date hereof, the Purchaser is purchasing the Units for its own account and not with a present view towards the public
    sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of
    1933, as amended ( the “Act”). 

 

	 	(b)	The
    Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under
    the Act

 

	 	(c)	The
    Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations
    of the Company and materials relating to the offer and sale of the Units which have been requested by the Purchaser or its
    advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information
    and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the
    Purchaser.

 

	 	(d)	Purchaser
    has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent,
    approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been
    obtained.

 

	 	(e)	The
    execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach
    of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach
    of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement,
    or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.

 

	 	6.	Company’s
    representations and warranties

 

	 	(a)	Company
    is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has
    the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
    approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been
    obtained. 

 

	 	(b)	The
    execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach
    of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach
    of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement,
    or instrument to which the Company is a party, or by which Company is or may be bound. 

 

    	2 

    	 

    

 

	 	7.	Restricted
    Securities Acknowledgement

 

Purchaser
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Act , and
shall contain the following restrictive legend:

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

	 	8.	Entire
    Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

	 	9.	Governing
    Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

    	3 

    	 

    

 

IN
WITNESS WHEREOF, the parties have hereunto executed this Agreement on the 2nd day of June, 2016.

	By:	 	 
	 	 	 
	Company	 	 
	 	 	 
	 	 	 
	 	 	 
	David
    Koos, CEO	 	 
	Regen
    Biopharma, Inc.	 	 
	 	 	 
	 	 	 
	Date:	 	 
	 	 	 
	Purchaser	 	 
	 	 	 
	 	 	 
	 	 	 
	By:	 	 
	Its:	 	 
	Date:
    6/1/2016	 	 
	 	 	 
	Number
    of Units Purchased:	1,000,000	 	 
	Total
    Purchase Price:	$50,000	 	 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]